ANGLE plc (GB:AGL) has released an update.
ANGLE plc has secured a deal with AstraZeneca to develop a Parsortix-based Androgen Receptor detection assay for prostate cancer research, valued at £550,000, with expectations to complete the project by Q1 2025. This collaboration could lead to significant long-term revenues for ANGLE as their technology may be utilized in numerous clinical trials. The assay aims to facilitate non-invasive monitoring of androgen receptor status, which is crucial in prostate cancer treatment and assessing therapeutic efficacy.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
